New cancer therapy by immunomanipulation: Development of immunotherapy for human melanoma as a model system

Cornea

Volumn 19, Issue 3 SUPPL. 1, 2000, Pages

  Kawakami, Yutaka ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Dendritic cells; Gp 100; Immunotherapy; Melanoma; Tumor antigens

Indexed keywords

EPITOPE; FREUND ADJUVANT; GLYCOPROTEIN GP 100; HLA A2 ANTIGEN; INTERLEUKIN 2; MELANOMA ANTIGEN; TUMOR REJECTION ANTIGEN;

ANTIGEN RECOGNITION; BINDING AFFINITY; CANCER IMMUNOTHERAPY; CONFERENCE PAPER; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; IMMUNIZATION; MELANOMA; PRIORITY JOURNAL; T LYMPHOCYTE; TREATMENT OUTCOME; TUMOR ESCAPE; TUMOR REGRESSION;

ANTIGENS, NEOPLASM; EYE NEOPLASMS; HUMANS; IMMUNOTHERAPY; MELANOMA; MEMBRANE GLYCOPROTEINS; MODELS, BIOLOGICAL; NEOPLASM PROTEINS; SKIN NEOPLASMS; T-LYMPHOCYTES;

EID: 0034038416     PISSN: 02773740     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003226-200005001-00002     Document Type: Conference Paper

References (27)

1. Kawakami Y. Immunotherapy using T cell defined tumor antigens for melanoma. Microbiol Immunol 1998;42:802-13.
2. Kawakami Y, Rosenberg SA. Human tumor antigens recognized by T-cells. Immunol Res 1997;16:313-39.
3. Old LJ, Chen YT. New paths in human cancer serology. J Exp Med 1998;187:1163-7.
4. Tureci O, Sahin U, Pfreundschuh M. Serological analysis of human tumor antigens: molecular definition and implications. Mol Med Today 1997;3:342-9.
5. Kawakami Y, Rosenberg S. T-cell recognition of self peptides as tumor rejection antigens. Immunol Res 1995;15:179-90.
6. Kawakami Y, Eliyahu S, Jennings C, et al. Recognition of multiple epitopes in the human melanoma antigen gp100 associated with in vivo tumor regression. J Immunol 1995;154:3961-8.
7. Cormier JN, Salgaller ML, Prevette T, et al. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J Sci Am 1997;3:37-44.
8. + cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo. Int J Cancer 1996;66:470-6.
9. Rosenberg SA, White DE. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J Immunother 1996;19:81-4.
10. Kawakami Y, Eliyahu S, Delgado CH, et al. Identification of a human melanoma antigen recognized by tumor infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 1994;91:6458-62.
11. Cormier J, Hijazi Y, Abati A, et al. Heterogeneous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in vivo. Int J Cancer 1998;75:517-24.
12. Van Pel A, van der Brugen P, Coulie PG, et al. Genes coding for tumor antigens recognized by cytolytic T lymphocytes. Immunol Rev 1995;145:229-50.
13. Marchand M, Weynants P, Rankin E, et al. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int J Cancer 1996;63:883-5.
14. Wolfel T, Hauer M, Schneider J, et al. A p161NK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 1995;269:1281-4.
15. Robbins PF, El-Gamil M, Li YF, et al. A mutated b-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med 1996;183:1185-92.
16. Mandruzzato S, Brasseur F, Andy G, et al. A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma. J Exp Med 1997;186:785-93.
17. Rubinfeld B, Robbins P, El-Gamil M, et al. Stabilization of beta-catenin by genetic defects in melanoma cell lines. Science 1997; 275:1790-2.
18. Parkhurst MR, Salgaller M, Southwood S, et al. Improved induction of melanoma reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A0201 binding residues. J Immunol 1996;157:2539-48.
19. Rosenberg S, Yang J, Schwartzentruber D, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998;4: 321-7.
20. Nestle F, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat Med 1998;4:328-32.
21. Rivoltini L, Kawakami Y, Sakaguchi K, et al. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J Immunol 1995;154:2257-65.
22. Salgaller M, Marincola F, Rivoltini L, et al. Recognition of multiple epitopes in the human melanoma antigen gp100 by antigen specific peripheral blood lymphocytes stimulated with synthetic peptides. Cancer Res 1995;55:4972-9.
23. Zhai Y, Yang JC, Kawakami Y, et al. Antigen-specific tumor vaccines: development and characterization of recombinant adenoviruses encoding MART-1 or gp100 for cancer therapy. J Immunol 1996;156:700-10.
24. Restifo NP, Marincola FM, Kawakami Y, et al. Loss of functional beta2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J Natl Cancer Inst 1996;88:100-8.
25. Kageshita T, Kawakami Y, Hirai S, Ono T. Differential expression of MART-1 in primary and metastatic melanoma lesions. J Immunother 1997;20:460-5.
26. Restifo NP, Kawakami Y, Marincola F, et al. Molecular mechanisms used by tumors to escape immune recognition: immunogen therapy and the cell biology of major histocompatibility complex class I. J Immunother 1993;14:182-90.
27. Hahne M, Rimoldi D, Schroter M, et al. Melanoma cell expression of Fas(Apo-1 CD95) ligand: implications for tumor immune escape. Science 1996;274:1363-6.